EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access

Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy

Murali Janakiram iD, Sabyasachi Ghosh, Victoria Alegria, Matthew Perciavalle iD, Bruno Emond iD, Jessica Maitland iD, Todd Bixby iD, Saurabh P Nagar, Zaina P Qureshi iD, Dimitra Rafailia Bakaloudi, Danai Dima iD

Journal of Comparative Effectiveness Research · 2026-07 · 15 (7)

DOI: 10.57264/cer-2026-0052 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-07. Verfasst von Murali Janakiram und 10 weiteren Autor:innen. Beteiligte Einrichtung: Judy & Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Patient Acceptance of Health Care, Health Care Costs. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ciltacabtagene autoleucel (cilta-cel) was approved for patients with relapsed or refractory multiple myeloma who received 1–3 prior lines of therapy in April 2024. Although traditionally administered inpatient (IP), there is an increasing trend in outpatient (OP) cilta-cel administration. However, few studies have quantified the healthcare resource utilization (HCRU) and cost implications of OP versus IP administration in clinical practice.

Aim

To compare HCRU and costs following OP versus IP administration of cilta-cel among patients with relapsed or refractory multiple myeloma after 1–3 prior lines of therapy. Materials & methods: This retrospective observational study used the Loopback Analytics electronic medical records database (28 February 2017 to 30 June 2025). We classified patients into OP or IP cohorts. All-cause and multiple myeloma-related HCRU and per-patient-per-month imputed costs were compared over 30 and 90 days post-infusion.

Results

There were 99 patients included (OP: 37; IP: 62). In the first 30 days post-infusion, 40.5% of the OP cohort did not require IP admission. Compared with the IP cohort, the OP cohort had significantly lower all-cause IP days (adjusted incidence rate ratio: 0.31; p < 0.001) and significantly lower all-cause IP-related imputed costs (adjusted mean difference: -$39,786; p < 0.001). Results were consistent over the first 90 days post-infusion and for multiple myeloma related HCRU and costs. Overall, OP administration was associated with an estimated cost savings of approximately $40,000 and $53,000 per patient in the first 30 and 90 days post-infusion, respectively.

Conclusion

OP administration of cilta-cel was associated with significantly lower IP resource utilization and imputed costs over the first 3 months post-infusion relative to IP administration, supporting the potential economic value and adoption of OP cilta-cel delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPatient Acceptance of Health CareHealth Care CostsHumansRetrospective StudiesFemaleMaleAgedMiddle AgedInpatientsOutpatientsHealth Resources

Stichwörter der Autor:innen

CAR-THCRUciltacabtagene autoleucelcostsinpatientmultiple myelomaoutpatientreal world

Autor:innen und Institutionen

  • Judy & Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA 91010, USA.
  • Johnson & Johnson, Horsham, PA 19044, USA.
  • Legend Biotech USA Inc, Somerset, NJ 08873, USA.
  • Analysis Group ULC, Montreal, QC, H3B 0G7, Canada.
  • Analysis Group ULC, Toronto, ON, M5X 1A9, Canada.
  • Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.

ORCID-Profile: Murali Janakiram, Matthew Perciavalle, Bruno Emond, Jessica Maitland, Todd Bixby, Zaina P Qureshi, Danai Dima

Zitieren

APA

Janakiram, M., Ghosh, S., Alegria, V., Perciavalle, M., Emond, B., Maitland, J., Bixby, T., Nagar, S. P., Qureshi, Z. P., Bakaloudi, D. R., & Dima, D. (2026). Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy. Journal of Comparative Effectiveness Research, 15(7). https://doi.org/10.57264/cer-2026-0052

Vancouver

Janakiram M, Ghosh S, Alegria V, Perciavalle M, Emond B, Maitland J, et al. Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy. Journal of Comparative Effectiveness Research. 2026;15(7). doi:10.57264/cer-2026-0052

BibTeX
@article{Janakiram2026,
  author = {Janakiram, Murali and Ghosh, Sabyasachi and Alegria, Victoria and Perciavalle, Matthew and Emond, Bruno and Maitland, Jessica and Bixby, Todd and Nagar, Saurabh P and Qureshi, Zaina P and Bakaloudi, Dimitra Rafailia and Dima, Danai},
  title = {Healthcare resource utilization and costs in patients with multiple myeloma administered ciltacabtagene autoleucel in outpatient versus inpatient settings after one to three prior lines of therapy},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.57264/cer-2026-0052}
}
Kostenlos starten →